0001786406-21-000002.txt : 20210329 0001786406-21-000002.hdr.sgml : 20210329 20210329115904 ACCESSION NUMBER: 0001786406-21-000002 CONFORMED SUBMISSION TYPE: SC 13G/A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20210329 DATE AS OF CHANGE: 20210329 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: Gain Therapeutics, Inc. CENTRAL INDEX KEY: 0001819411 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 851726310 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-92410 FILM NUMBER: 21780298 BUSINESS ADDRESS: STREET 1: 4800 HAMPDEN LANE STREET 2: SUITE 200 CITY: BETHESDA STATE: MD ZIP: 20814 BUSINESS PHONE: (301) 500-1556 MAIL ADDRESS: STREET 1: 4800 HAMPDEN LANE STREET 2: SUITE 200 CITY: BETHESDA STATE: MD ZIP: 20814 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: Titcomb Shawn CENTRAL INDEX KEY: 0001786406 FILING VALUES: FORM TYPE: SC 13G/A MAIL ADDRESS: STREET 1: 900 N. FEDERAL HWY., SUITE 400 CITY: BOCA RATON STATE: FL ZIP: 33432 SC 13G/A 1 titcomb13g.txt TITCOMB 13G - GAIN THERAPEUTICS, INC. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ___)* Gain Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 36269B105 (CUSIP Number) March 29, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed:[_] Rule 13d-1(b) [_] Rule 13d-1(c) [X] Rule 13d-1(d) *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). SCHEDULE 13G CUSIP No. 36269B105 1. Names of Reporting Persons: Shawn Milemore Titcomb Revocable Trust 2. Check the appropriate box if a member of a Group (see instructions) (a)[ ](b)[ ] 3. Sec Use Only 4. Citizenship or Place of Organization: United States Number of Shares Beneficially Owned by Each Reporting Person With: 5. Sole Voting Power: 729,737 6. Shared Voting Power: 0 7. Sole Dispositive Power: 729,737 8. Shared Dipositive Power: 9. Aggregate Amount Beneficially Owned by Each Reporting Person: 729,737 10. Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)[ ] 11. Percent of class represented by amount in row (9): 6.1% 12. Type of Reporting Person (See Instructions): IN Item 1. (a) Name of Issuer: Gain Therapeutics, Inc. (b) Address of Issuer's Principal Executive Offices: 4800 Hampden Lane, Suite 200, Bethesda, MD 20814 Item 2. (a) Name of Person Filing: Shawn Milemore Titcomb Revocable Trust (b) Address of Principal Business Office or, if None, Residence: 900 N. Federal Hwy., Suite 400, Boca Raton, Florida 33432 (c) Citizenship: United States (d) Title and Class of Securities: Common Stock, $0.0001 par value per share ("Common Stock") (e) CUSIP No.: 36269B105 Item 3. If this statement is filed pursuant to 240.13d-1(b) or 240.13d-2(b) or(c), check whether the person filing is a: None of the categories are applicable to the undersigned. Item 4. Ownership (a) Amount Beneficially Owned: 729,737 (b) Percent of Class: The information set forth in Rows 5 through 11 on the cover page for the Reporting Person is hereby incorporated by reference into this Item 4(b) for the Reporting Person. The percentages reported herein are calculated on the basis of a total of 11,876,460 shares of Common Stock outstanding as of the date hereof, based on a statement in the Company's Form S-1, and subsequent 8-k filed with the Securities and Exchange Commission (the "SEC") on February 19, 2021 and March 22, 2021 respectively. (c) Number of shares as to which such person has: (i) Sole power to vote or to direct the vote: 729,737 (ii) Shared power to vote or to direct the vote: 0 (iii) Sole power to dispose or to direct the disposition of: 729,737 (iv) Shared power to dispose or to direct the disposition of: 0 Item 5. Ownership of Five Percent or Less of a Class. Not Applicable. If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ ]. Item 6. Ownership of more than Five Percent on Behalf of Another Person. Not Applicable. Item 7. Identification and classification of the subsidiary which acquired the security being reported on by the parent holding company or control person. Not Applicable. Item 8. Identification and classification of members of the group. Not Applicable. Item 9. Notice of Dissolution of Group. Not Applicable. Item 10. Certifications. SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Dated: March 29, 2021 SHAWN MILEMORE TITCOMB REVOCABLE TRUST /s/ Shawn Titcomb Shawn Titcomb Trustee The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative (other than an executive officer or general partner of this filing person), evidence of the representative's authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature. Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001). Page 6 of 6